

Certificate of Analysis for NR-55509

Klebsiella pneumoniae, Strain MRSN 5741

Catalog No. NR-55509

This reagent is the tangible property of the U.S. Government.

Product Description:

Klebsiella pneumoniae (K. pneumoniae), strain MRSN 5741 was isolated in 2003 from a human respiratory sample in North America as part of a global surveillance program. NR-55509 was deposited as a multidrug-resistant strain, sensitive to amikacin, cefepime, ceftazidime/avibactam, ertapenem, imipenem, meropenem, tetracycline and tigecycline, intermediately resistant to gentamicin and tobramycin and resistant to ampicillin/sulbactam, aztreonam, ceftazidime, ceftolozane/tazobactam, ceftriaxone, ciprofloxacin, levofloxacin, piperacillin/tazobactam and trimethoprim/sulfamethoxazole. NR-55509 was produced by inoculation of the deposited material into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot. Quality control testing was completed under propagation conditions unless otherwise noted.

Lot: 70049666 Manufacturing Date: 06JAN2022

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Certificate of Analysis contains complex tables and may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided: E-mail: contact@BEIResources.org. We try to respond to feedback within 24 hours.

| TEST | SPECIFICATIONS | RESULTS |
|--|--|---|
| Phenotypic Analysis | | |
| Cellular morphology | Gram-negative rods | Gram-negative rods |
| Colony morphology | Report results | Circular, convex, entire, smooth, mucoid and cream (Figure 1) |
| Motility (wet mount) | Report results | Non-motile |
| VITEK [®] 2 (GN card) | K. pneumoniae (≥ 89%) | K. pneumoniae (98%) |
| Antibiotic Susceptibility Profile ^{1,2} | | |
| Amikacin | Sensitive | Sensitive (≤ 2 µg/mL) |
| Ampicillin/sulbactam | Resistant | Resistant (≥ 32 µg/mL) |
| Aztreonam | Resistant | Sensitive (4 µg/mL) ³ |
| Cefepime | Sensitive | Sensitive (≤ 1 µg/mL) |
| Ceftazidime | Resistant | Resistant (≥ 64 µg/mL) |
| Ceftazidime/avibactam | Sensitive | Sensitive (6 µg/mL) |
| Ceftolozane/tazobactam | Resistant | Inconclusive ⁴ |
| Ceftriaxone | Resistant | Resistant (8 to 12 µg/mL) |
| Ciprofloxacin | Resistant | Resistant (≥ 32 µg/mL) |
| Ertapenem | Sensitive | Sensitive (≤ 0.5 μg/mL) |
| Gentamicin | Intermediate | Intermediate (8 µg/mL) |
| Imipenem | Sensitive | Sensitive (0.19 µg/mL) |
| Levofloxacin | Resistant | Resistant (≥ 8 μg/mL) |
| Meropenem | Sensitive | Sensitive (≤ 0.25 μg/mL) |
| Piperacillin/tazobactam | Resistant | Resistant (≥ 128 µg/mL) |
| Tetracycline | Sensitive | Sensitive (4 µg/mL) |
| Tigecycline | Sensitive | Sensitive (0.38 μg/mL) ⁵ |
| Tobramycin | Intermediate | Intermediate (8 µg/mL) |
| Trimethoprim/sulfamethoxazole | Resistant | Resistant (≥ 320 µg/mL) |
| Genotypic Analysis | | |
| Sequencing of 16S ribosomal RNA gene (~ 1480 base pairs) | ≥ 99% sequence identity to K. pneumoniae, strain MRSN 5741 (GenBank: JAGYEX010000090.1) | 99.8% sequence identity to K. pneumoniae, strain MRSN 5741 (GenBank: JAGYEX010000090.1) ⁶ |

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898



Certificate of Analysis for NR-55509

| TEST | SPECIFICATIONS | RESULTS |
|---|----------------|---|
| Purity 7 days at 37°C in an aerobic atmosphere with 5% CO ₂ on Tryptic Soy agar with 5% defibrinated sheep blood | morphology | Growth consistent with expected colony morphology |
| Viability | Growth | Growth |

¹Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)

Figure 1: Colony Morphology



/Sonia Bjorum Brower/ Sonia Bjorum Brower

21 JUL 2022

Lead Technical Writer or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org
Tel: 800-359-7370

Fax: 703-365-2898

²Antibiotic susceptibility was tested using a combination of bioMérieux VITEK®2 GN74 and ETEST®.

³K. pneumoniae, strain MRSN 5741 was deposited as resistant to aztreonam, but showed a MIC of 4 μg per mL (interpreted as sensitive) for this antibiotic during QC testing. Testing was performed in duplicate.

⁴K. pneumoniae, strain MRSN 5741 was deposited as resistant to ceftolozane/tazobactam. Antibiotic susceptibility testing performed in quadruplicate determined that for strain MRSN 5741, the ceftolozane/tazobactam MICs are 3 and 4 μg per mL, which are interpreted as sensitive and intermediately resistant, respectively.

⁵MIC Interpretation Guideline: EUCAST Version 8.0 (2018)

⁶Also consistent with other *Klebsiella* species